• Milestone Pharmaceuticals initiates Phase 3 ReVerA-301 trial of etripamil nasal spray (Cardamyst) for AFib-RVR

  Milestone Pharmaceuticals has announced the initiation of the Phase 3 ReVeRA-301 study of etripamil nasal spray in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). The trial is expected to enroll about 150 patients who… [Read more . . .]

• Silo Pharma gets notice of allowance for Canadian patent covering SPC-15 intranasal therapy for PTSD

  According to Silo Pharma, the company has received a notice of allowance from the Canadian Intellectual Property Office related to a patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” covering SPC-15… [Read more . . .]

• Rein Therapeutic’s LTI-03 inhaled dry powder synthetic peptide gets Fast Track designation for the treatment of IPF

  According to Rein Therapeutics, the FDA has granted the company’s LTI-03 inhaled dry powder synthetic peptide Fast Track designation for the treatment of idiopathic pulmonary fibrosis. The company notes that the FDA previously granted orphan… [Read more . . .]

• Bespak’s Holmes Chapel site gets Gold EcoVadis sustainability rating

  Inhalation specialist CDMO Bespak announced that its Holmes Chapel, UK site has again received a Gold EcoVadis sustainability rating, the second since Bespak was spun out from Recipharm in 2024. Earlier this year, Bespak and… [Read more . . .]

• NeOnc reports that Phase 2a trial of NEO100 intranasal perillyl alcohol in patients with brain tumors met its primary endpoint

  NeOnc Technologies announced that the Phase 2a NEO100-01 study of NEO100 intranasal perillyl alcohol in patients with Grade 3 and Grade 4 IDH1-mutant gliomas met its primary endpoint, achieving a 48.9% 6-month progression-free survival rate.… [Read more . . .]

• Scienture launches Rezenopy naloxone nasal spray in the US

• Zydus launches Revahale revefenacin inhalation solution for the treatment of COPD in India

• ReCode Therapeutics names Heather Clark as its new CEO

• Harrow acquires Tyrvaya varenicline nasal spray for the treatment of dry eye disease

• Savara gets 2 new patents covering Molbreevi molgramostim inhalation solution

More news . . .